The Cholesterol Wars: Navigating a Shifting Battlefield

Date
Sep 9 12:00pm -
Sep 30 1:00pm
Location
Zoom
Table of Contents
  1. Program Description
  2. Registration/Cost
  3. Accreditation

Program Description

Statin therapy is the recommended treatment for lowering low-density lipoprotein cholesterol (LDL-C) and reducing atherosclerotic cardiovascular disease (ASCVD) risk. However, evidence-based and guideline-recommended therapies, including ezetimibe and PCSK9 inhibitors, continue to be underutilized, even among the highest risk patients. Consequently, an unmitigated burden of cardiovascular risk persists. More education is urgently needed to address this problem. To that end, NATF invites you to join us for a virtual series of webinars that discuss some of these key issues in cholesterol management. Covered topics include:

Week 1: Identifying Patients Who Would Benefit from PCSK9 Inhibitors
Friday, September 9, 2022
12:00-1:00 PM EST
Moderated by Allen Taylor, MD
Didactic lecture: Jorge Plutzky, MD
Case presentation: Anum Saeed, MD


Week 2: The Critical Importance of Lowering LDL-C in High-Risk Patients
Friday, September 16, 2022
12:00-1:00 PM EST
Moderated by Allen Taylor, MD
Didactic lecture: Ty Gluckman, MD
Case presentation: Margo B. Minissian, PhD, ACNP, FAHA


Week 3: Recent Cholesterol Guidelines and Integration into Clinical Practice
Friday, September 23, 2022
12:00-1:00 PM EST
Moderated by Jorge Plutzky, MD
Didactic lecture: Lynne Braun, PhD, CNP
Case presentation: Joyce Ross, NP


Week 4: Current Treatments for LDL Lowering — and Why Patient Access Is So Important
Friday, September 30, 2022
12:00-1:00 PM EST
Moderated by Jorge Plutzky, MD
Didactic lecture: Heather Johnson, MD
Case presentation: Seth Martin, MD, MHS

Registration/Cost

Registration is $25 and allows you access to all webinars in the series. You only need to register once. Webinars will be 12:00-1:00PM EST every Friday from September 9-30.

Accreditation

Physicians: 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of ScientiaCME and the North American Thrombosis Forum. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians. 

ScientiaCME designates each live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. 

Nurse Practitioners (NPs): The American Academy of Nurse Practitioners accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. ScientiaCME will provide NPs who successfully complete each activity with a certificate of participation indicating that the activity was designated for AMA PRA Category 1 Credit(s)™

Physician Assistants: The American Academy of Physician Assistants accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. 

Nurses: may claim credit for activities approved for AMA PRA Category 1 Credit(s)™ in most states for up to 50% of the nursing requirement for recertification. Nursing board continuing education requirements for relicensure vary state-by-state. 

Medical Practice Executives: The American College of Medical Practice Executives accepts AMA PRA Category 1 Credit(s)TM from organizations accredited by ACCME. 

Pharmacists: 

ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Each activity is approved for 1.0 hour (0.1 CEUs) of continuing pharmacy education credit. Proof of participation will be posted within 4 to 6 weeks to the NABP CPE profiles of participants who have successfully completed the post-test with a passing score of 70%. Participants have 1 calendar month after each activity to provide learner information and complete the post-activity assessment and evaluation. ACPE UANs:

  • New Strategies To Help Your Patients Achieve LDL-C Targets: Helping clinicians identify which patients would benefit from PCSK9 inhibitors: 0574-9999-22-041-L01-P
  • New Strategies To Help Your Patients Achieve LDL-C Targets: Educating clinicians on the critical importance of lowering LDL-C in high-risk patients: 0574-9999-22-042-L01-P
  • New Strategies To Help Your Patients Achieve LDL-C Targets: Reviewing the most recent cholesterol guidelines and integration into clinical practice: 0574-9999-22-043-L01-P
  • New Strategies To Help Your Patients Achieve LDL-C Targets: Describing all current treatment options available (and why access to those treatments is so important): 0574-9999-22-044-L01-P

These activities are Application (A)-type activities. 

More information coming soon!